5Suppliers
0Customers
1Debt Items
0Related Chains

MiNK Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
AGENUS AGENUS 90% Agenus has also agreed to provide the Company with Agenus' biological material upon written request in order for the Company to use such material in its development activities of a combination therapy.
AGENUS-INC AGENUS-INC 90% Mr. Charette, provides services to the Company through an Amended and Restated Intercompany Services Agreement between the Company and Agenus.
AUTONOMOUS-THERAPEUTICS AUTONOMOUS-THERAPEUTICS 90% Advance research collaboration with Autonomous Therapeutics(October 2024) to evaluate encrypted RNA™ technologies in combination with MiNK-215 and agenT-797 in metastatic solid tumor models;
C-FURTHER C-FURTHER 90% Leverage a collaboration with C-Further to support an optimal TCR-PRAME candidate for pediatric patients with cancer.
IMMUNOSCAPE IMMUNOSCAPE 90% A collaboration with Immunoscape (December 2023) to discover and develop TCR-based therapies across multiple immune cell modalities;

MiNK Therapeutics, Inc. Customers

No clients on recordNo downstream customers found in our database for MiNK Therapeutics, Inc..

MiNK Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
INKT-DEBT-10286 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.

MiNK Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for MiNK Therapeutics, Inc..

MiNK Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
INKT-OWNER-HORIZON-FINANCIAL-SERVICES-LLC HORIZON FINANCIAL SERVICES, LLC 90% 13F overlay lists HORIZON FINANCIAL SERVICES, LLC as top holder; 1 tracked holders.

MiNK Therapeutics, Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.